ImmunityBio, Inc. (IBRX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $9.80
- As of
Kresmion compiles this page from IBRX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ImmunityBio, Inc. (IBRX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-14.
See the full IBRX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for IBRX on one page. Preview it with sample data, then open it live with a free account.
Preview the IBRX dossierActive signals for IBRX
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 139.7%, EPS $-0.22 vs $-0.0918 estimate
- highCONSENSUS_BUY
3 tracked funds increased IBRX this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +172% to IBRX (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 78% of IBRX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +513% to IBRX (2026Q2)
FREE, NO ACCOUNT
Every signal on IBRX, as it fires
You are seeing 5 of 15 signals recorded on IBRX since 2026-05-26.
The five above landed across 2 days. The other 10 were recorded on 2 other days. 9 of the 15 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in IBRX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 45256X103 · 2026Q2 | $101.1M | 0.05% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 45256X103 · 2026Q2 | $97.2M | 0.07% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 45256X103 · 2026Q2 | $48.9M | 0.02% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 45256X103 · 2026Q2 | $9M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 45256X103 · 2026Q2 | $1.2M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, IBRX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
IBRX against its peers
IBRX's operating margin of -226.0% ranks in the 26th percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-01-02.
| Metric | IBRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 113M USD | 616M USD | 36 | 17 |
| Operating margin | -226.0% | -6.7% | 26 | 16 |
| Net margin | -310.2% | -19.2% | 21 | 16 |
| Return on equity | n/a | -21.2% | n/a | 19 |
| P / E | n/a | 29.9x | n/a | 6 |
| 1 year | 295.2% | 54.4% | 86 | 17 |
Peers (23): PCVX, MDGL, BMRN, APGE, HALO, KRYS, NUVL, BBIO, PTGX, KYMR, CRNX, SMMT, CYTK, NBIX, TGTX, CAI, EXEL, ARWR, ASND, SYRE, ABVX, IONS, PRAX. Left out: SBMFF (no annual filing), BCHMY (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-01-02. Every figure is one full fiscal year read from one annual filing (IBRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow IBRX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to IBRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.